Solid IO
Founded 2025 · 13 employees on LinkedIn · 4 known investors
Solid IO develops a tumor-on-chip platform using organ-on-chip technology and AI to model patient-specific tumor microenvironments for oncology and immunotherapy research. The platform enables pharmaceutical companies, biotech firms, and cancer clinics to predict treatment responses, accelerate drug development, and support precision medicine in cancer care.
Investors · 4
Frequently asked questions
- What does Solid IO do?
- Solid IO develops a tumor-on-chip platform using organ-on-chip technology and AI to model patient-specific tumor microenvironments for oncology and immunotherapy research. The platform enables pharmaceutical companies, biotech firms, and cancer clinics to predict treatment responses, accelerate drug development, and support precision medicine in cancer care.
- Who are Solid IO's investors?
- Solid IO's investors include Leo Capital, BSV Ventures, Leo Capital Ventures, Nordic Science Investments.